Shopping Cart
Remove All
Your shopping cart is currently empty
Lucatumumab (Synonyms: HCD122, HCD 122, CHIR-12.12)
Catalog No. T76729 Copy Product Info
🥰Excellent
Lucatumumab (HCD122) is a fully human anti-CD40 monoclonal antibody with antitumor activity that blocks the interaction of CD40L with CD40 and inhibits the CD40/CD40L-mediated signaling pathway for the study of chronic lymphocytic leukemia (CLL) and multiple myeloma.
Lucatumumab
Copy Product Info🥰Excellent
Catalog No. T76729
Synonyms HCD122, HCD 122, CHIR-12.12
Lucatumumab (HCD122) is a fully human anti-CD40 monoclonal antibody with antitumor activity that blocks the interaction of CD40L with CD40 and inhibits the CD40/CD40L-mediated signaling pathway for the study of chronic lymphocytic leukemia (CLL) and multiple myeloma.
Lucatumumab
Cas No. 903512-50-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | In Stock | In Stock | |
| 5 mg | $448 | In Stock | In Stock | |
| 10 mg | $728 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,480 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.5% (SDS-PAGE); 98.4% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Lucatumumab (HCD122) is a fully human anti-CD40 monoclonal antibody with antitumor activity that blocks the interaction of CD40L with CD40 and inhibits the CD40/CD40L-mediated signaling pathway for the study of chronic lymphocytic leukemia (CLL) and multiple myeloma. |
| In vitro | Lucatumumab (0.001-10 μg/mL; 4 hours) lysed B-cell chronic lymphocytic leukemia (B-CLL) cells by antibody-dependent cell-mediated cytotoxicity (ADCC) action, achieving a mean maximum lysis rate of 49%. [1] Lucatumumab (0.1-10 μg/mL; 3 days) was able to decrease CD40L-induced signaling and reduce B-CLL cell viability. [1] Lucatumumab (10 μg/mL; 24 hours) is able to inhibit cytokine secretion by B-CLL cells. [1] |
| Synonyms | HCD122, HCD 122, CHIR-12.12 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF5/CD40 |
| Molecular Weight | 146.15 kDa |
| Cas No. | 903512-50-5 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Lucatumumab | purchase Lucatumumab | Lucatumumab cost | order Lucatumumab | Lucatumumab in vitro | Lucatumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.